Abstract
Background and Purpose: Synaptic vesicle protein2A(SV2A) is the specific binding site of the anti‐epileptic drug levetiracetam (LEV) and its higher affinity analogueUCB30889. Moreover, the protein has been well validated as a target for anticonvulsant therapy. Here, we report the identification ofUCB1244283acting as aSV2Apositive allosteric modulator ofUCB30889.Experimental Approach: UCB1244283was characterizedin vitrousing radioligand binding assays with[3H]UCB30889on recombinantSV2Aexpressed inHEKcells and on rat cortex.In vivo, the compound was tested in sound‐sensitive mice.Key Results: Saturation binding experiments in the presence ofUCB1244283demonstrated a fivefold increase in the affinity of[3H]UCB30889for human recombinantSV2A, combined with a twofold increase of the total number of binding sites. Similar results were obtained on rat cortex. In competition binding experiments,UCB1244283potentiated the affinity ofUCB30889while the affinity ofLEVremained unchanged.UCB1244283significantly slowed down both the association and dissociation kinetics of[3H]UCB30889. Following i.c.v. administration in sound‐sensitive mice,UCB1244283showed a clear protective effect against both tonic and clonic convulsions.Conclusions and Implications: These results indicate thatUCB1244283can modulate the conformation ofSV2A, thereby inducing a higher affinity state forUCB30889. Our results also suggest that the conformation ofSV2A per semight be an important determinant of its functioning, especially during epileptic seizures. Therefore, agents that act on the conformation ofSV2Amight hold great potential in the search for newSV2A‐based anticonvulsant therapies.

This publication has 36 references indexed in Scilit: